
2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
An interview with Doug Hausner, C-SOPS, about continuous manufacturing
Continuous manufacturing offers the potential for improved quality, higher production efficiency, and smaller, more flexible equipment. Doug Hausner, Associate Director for the Engineering Research Center for Structured Organic Particulate Systems (C-SOPS) based at Rutgers University in New Jersey, USA, speaks with Pharmaceutical Technology about the current and future use of continuous processes in solid-dosage drug production.